Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse

Blood Cancer J. 2023 Jun 22;13(1):94. doi: 10.1038/s41408-023-00873-z.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Arsenic Trioxide / adverse effects
  • Arsenicals* / adverse effects
  • Humans
  • Leukemia, Promyelocytic, Acute* / complications
  • Leukemia, Promyelocytic, Acute* / drug therapy
  • Oxides / adverse effects
  • Recurrence
  • Tretinoin / therapeutic use

Substances

  • Arsenic Trioxide
  • Tretinoin
  • Oxides
  • Arsenicals
  • Antineoplastic Agents